These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32276476)

  • 1. Human Clinical Relevance of the Porcine Model of Pseudoallergic Infusion Reactions.
    Szebeni J; Bawa R
    Biomedicines; 2020 Apr; 8(4):. PubMed ID: 32276476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals.
    Szebeni J
    Mol Immunol; 2014 Oct; 61(2):163-73. PubMed ID: 25124145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines.
    Szebeni J; Bedőcs P; Csukás D; Rosivall L; Bünger R; Urbanics R
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1706-16. PubMed ID: 22820530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Acute Anaphylactoid Reactogenicity of Nanoparticle-Containing Medicines and Vaccines Using the Porcine CARPA Model.
    Szebeni J
    Methods Mol Biol; 2024; 2789():229-243. PubMed ID: 38507008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Critical Choice of Animal Models in Nanomedicine Safety Assessment: A Lesson Learned From Hemoglobin-Based Oxygen Carriers.
    Bedőcs P; Szebeni J
    Front Immunol; 2020; 11():584966. PubMed ID: 33193403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.
    Szebeni J
    Toxicology; 2005 Dec; 216(2-3):106-21. PubMed ID: 16140450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions.
    Kozma GT; Mészáros T; Vashegyi I; Fülöp T; Örfi E; Dézsi L; Rosivall L; Bavli Y; Urbanics R; Mollnes TE; Barenholz Y; Szebeni J
    ACS Nano; 2019 Aug; 13(8):9315-9324. PubMed ID: 31348638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs.
    Fülöp T; Kozma GT; Vashegyi I; Mészáros T; Rosivall L; Urbanics R; Storm G; Metselaar JM; Szebeni J
    J Control Release; 2019 Sep; 309():333-338. PubMed ID: 31295544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization.
    Mészáros T; Kozma GT; Shimizu T; Miyahara K; Turjeman K; Ishida T; Barenholz Y; Urbanics R; Szebeni J
    Int J Nanomedicine; 2018; 13():6345-6357. PubMed ID: 30349254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses.
    Dézsi L; Fülöp T; Mészáros T; Szénási G; Urbanics R; Vázsonyi C; Őrfi E; Rosivall L; Nemes R; Kok RJ; Metselaar JM; Storm G; Szebeni J
    J Control Release; 2014 Dec; 195():2-10. PubMed ID: 25148822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents.
    Szebeni J
    Crit Rev Ther Drug Carrier Syst; 2001; 18(6):567-606. PubMed ID: 11789676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model.
    Jackman JA; Mészáros T; Fülöp T; Urbanics R; Szebeni J; Cho NJ
    Nanomedicine; 2016 May; 12(4):933-943. PubMed ID: 26767512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation in vitro and reactogenicity of low-molecular weight dextran-coated SPIONs in the pig CARPA model: Correlation with physicochemical features and clinical information.
    Fülöp T; Nemes R; Mészáros T; Urbanics R; Kok RJ; Jackman JA; Cho NJ; Storm G; Szebeni J
    J Control Release; 2018 Jan; 270():268-274. PubMed ID: 29203414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational gaps in animal models of human infusion reactions to nanomedicines.
    Moghimi SM; Simberg D
    Nanomedicine (Lond); 2018 May; 13(9):973-975. PubMed ID: 29790401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs.
    Szebeni J; Storm G
    Biochem Biophys Res Commun; 2015 Dec; 468(3):490-7. PubMed ID: 26182876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infusion Reactions Associated with the Medical Application of Monoclonal Antibodies: The Role of Complement Activation and Possibility of Inhibition by Factor H.
    Fülöp T; Mészáros T; Kozma GT; Szebeni J; Józsi M
    Antibodies (Basel); 2018 Mar; 7(1):. PubMed ID: 31544866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles.
    Szebeni J; Alving CR; Rosivall L; Bünger R; Baranyi L; Bedöcs P; Tóth M; Barenholz Y
    J Liposome Res; 2007; 17(2):107-17. PubMed ID: 17613700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management.
    Szebeni J; Fishbane S; Hedenus M; Howaldt S; Locatelli F; Patni S; Rampton D; Weiss G; Folkersen J
    Br J Pharmacol; 2015 Nov; 172(21):5025-36. PubMed ID: 26265306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model.
    Szebeni J; Bedőcs P; Urbanics R; Bünger R; Rosivall L; Tóth M; Barenholz Y
    J Control Release; 2012 Jun; 160(2):382-7. PubMed ID: 22421426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
    Szebeni J; Muggia F; Gabizon A; Barenholz Y
    Adv Drug Deliv Rev; 2011 Sep; 63(12):1020-30. PubMed ID: 21787819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.